Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 8/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633048 | 0.80 | CYP2C9 (0.41) | FFAR1ACACB | |
| SCHEMBL16633288 | 0.78 | NPSR1 (0.45) | PARP10ACACBACACA | |
| SCHEMBL16634014 | 0.77 | DAGLA (0.41) | — | |
| SCHEMBL16633588 | 0.76 | ESR1 (0.43) | — | |
| SCHEMBL2574635 | 0.74 | CYP1A2 (0.38) | — | |
| SCHEMBL16563380 | 0.74 | GPR88 (0.59) | FFAR1GPR88PARP15PARP10PARP2 | |
| SCHEMBL2502217 | 0.73 | FFAR1 (0.52) | FFAR1GPR88 | |
| SCHEMBL21910441 | 0.71 | PARP15 (0.49) | FFAR1GPR88PARP15PARP10PARP2 | |
| SCHEMBL6349734 | 0.71 | TAS1R3 (0.43) | — | |
| SCHEMBL17603763 | 0.70 | BMP1 (0.43) | GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | FFAR1 2499/4885GPR88 2229/4885PARP15 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.